← All Novelstem International CORP filings

Novelstem International CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OTC.Pink
NSTM
Novelstem International CORP
10-K: NovelStem International Corp. Reports Significant Losses and Impairment in 2024 10-K Filing
NovelStem International Corp.'s 2024 10-K filing reveals substantial net losses, an impairment of its NewStem investment, and ongoing concerns about its ability to continue as a going concern.
OTC.Pink
NSTM
Novelstem International CORP
10-K: NovelStem International Corp. Reports $4.2 Million Net Loss in 2023 Amidst Biotech Development Challenges
NovelStem International Corp. reported a net loss of $4.2 million for 2023, primarily due to losses from its investment in NewStem and litigation expenses.